Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma

被引:238
作者
Ichikawa, A [1 ]
Kinoshita, T [1 ]
Watanabe, T [1 ]
Kato, H [1 ]
Nagai, H [1 ]
Tsushita, K [1 ]
Saito, H [1 ]
Hotta, T [1 ]
机构
[1] NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN
关键词
D O I
10.1056/NEJM199708213370804
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma. Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing. Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan-Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P<0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk. Conclusions Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma. (C) 1997, Massachusetts Medical Society.
引用
收藏
页码:529 / 534
页数:6
相关论文
共 49 条
  • [31] REARRANGEMENT OF THE BCL-6 GENE AS A PROGNOSTIC MARKER IN DIFFUSE LARGE-CELL LYMPHOMA
    OFFIT, K
    LOCOCO, F
    LOUIE, DC
    PARSA, NZ
    LEUNG, D
    PORTLOCK, C
    YE, BH
    LISTA, F
    FILIPPA, DA
    ROSENBAUM, A
    LADANYI, M
    JHANWAR, S
    DALLAFAVERA, R
    CHAGANTI, RSK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (02) : 74 - 80
  • [32] RAPID AND SENSITIVE DETECTION OF POINT MUTATIONS AND DNA POLYMORPHISMS USING THE POLYMERASE CHAIN-REACTION
    ORITA, M
    SUZUKI, Y
    SEKIYA, T
    HAYASHI, K
    [J]. GENOMICS, 1989, 5 (04) : 874 - 879
  • [33] PUI CH, 1987, BLOOD, V70, P624
  • [34] RODRIGUEZ V, 1977, BLOOD, V49, P325
  • [35] ROSENBERG SA, 1982, CANCER, V49, P2112
  • [36] NUCLEAR OVEREXPRESSION OF P53-PROTEIN IN TRANSITIONAL CELL BLADDER-CARCINOMA - A MARKER FOR DISEASE PROGRESSION
    SARKIS, AS
    DALBAGNI, G
    CORDONCARDO, C
    ZHANG, ZF
    SHEINFELD, J
    FAIR, WR
    HERR, HW
    REUTER, VE
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (01) : 53 - 59
  • [37] SCHOUTEN HC, 1990, BLOOD, V75, P1841
  • [38] CHEMOTHERAPEUTIC RESULTS AND PROGNOSTIC FACTORS OF PATIENTS WITH ADVANCED NON-HODGKINS LYMPHOMA TREATED WITH VEPA OR VEPA-M
    SHIMOYAMA, M
    OTA, K
    KIKUCHI, M
    YUNOKI, K
    KONDA, S
    TAKATSUKI, K
    ICHIMARU, M
    OGAWA, M
    KIMURA, I
    TOMINAGA, S
    TSUGANE, S
    TAGUCHI, H
    MINATO, K
    TAKENAKA, T
    TOBINAL, K
    KURITA, S
    OYAMA, A
    HISANO, S
    KOZURU, M
    MATSUMOTO, M
    NOMURA, K
    TAKIGUCHI, T
    SUGAI, S
    YAMAGUCHI, K
    HATTORI, T
    KINOSHITA, K
    TAJIMA, K
    SUEMASU, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) : 128 - 141
  • [39] A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA
    SHIPP, MA
    HARRINGTON, DP
    ANDERSON, JR
    ARMITAGE, JO
    BONADONNA, G
    BRITTINGER, G
    CABANILLAS, F
    CANELLOS, GP
    COIFFIER, B
    CONNORS, JM
    COWAN, RA
    CROWTHER, D
    DAHLBERG, S
    ENGELHARD, M
    FISHER, RI
    GISSELBRECHT, C
    HORNING, SJ
    LEPAGE, E
    LISTER, TA
    MEERWALDT, JH
    MONTSERRAT, E
    NISSEN, NI
    OKEN, MM
    PETERSON, BA
    TONDINI, C
    VELASQUEZ, WA
    YEAP, BY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) : 987 - 994
  • [40] IDENTIFICATION OF MAJOR PROGNOSTIC SUBGROUPS OF PATIENTS WITH LARGE-CELL LYMPHOMA TREATED WITH M-BACOD OR M-BACOD
    SHIPP, MA
    HARRINGTON, DP
    KLATT, MM
    JOCHELSON, MS
    PINKUS, GS
    MARSHALL, JL
    ROSENTHAL, DS
    SKARIN, AT
    CANELLOS, GP
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) : 757 - 765